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Abstract 
Diabetic nephropathy (DN) is a severe micro vascular complication accompanying diabetes mellitus that affects mil‑
lions of people worldwide. End‑stage renal disease occurs in nearly half of all DN patients, resulting in large medical 
costs and lost productivity. The course of DN progression is complicated, and effective and safe therapeutic strategies 
are desired. While the complex nature of DN renders medicines with a single therapeutic target less efficacious, Chi‑
nese medicine, with its holistic view targeting the whole system of the patient, has exhibited efficacy for DN manage‑
ment. This review aims to describe the experimental evidence for Chinese medicines in DN management, with an 
emphasis on the underlying mechanisms, and to discuss the combined use of herbs and drugs in DN treatment.
© 2016 Liu et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Diabetic nephropathy (DN) is a serious micro vascular 
complication in patients with diabetes mellitus (DM), 
affecting approximately 40  % of patients with type 1 or 
type 2 DM [1, 2]. It is the predominant cause of chronic 
kidney disease and renal failure, and is closely associated 
with many micro vascular diseases, leading to financial 
and medicinal burdens [3]. Continued hyperglycemia 
associated with DM is the major cause of kidney dysfunc-
tion with metabolic and hemodynamic disorders arising 
from oxidative stress and inflammation [4].
During DN progression, progressive alterations devel-
opfrom hyperfiltration through micro albuminuria to 
macro albuminuria, and finally to renal failure [5]. Renal 
structural changes are found in the nephrons, espe-
cially in the primary part of the glomerulus, including 
podocyte loss, glomerular basement membrane (GBM) 
thickening, endothelial cell dysfunction, and mesan-
gial extracellular matrix (ECM) expansion, resulting in 
protein leakage into the urine [6]. Pulmonary dysfunction 
[7], hyperlipidemia and non-alcoholic fatty liver disease 
[8], cardiovascular disease [9], and even heart failure [10] 
have been reported to be positively associated with DN 
progression. Therefore, synergistic therapies targeting 
multiple mediators of DN are required for effective thera-
peutic strategies [4].
The experimental models used for studying Chi-
nese medicines (CMs) in DN treatment are diverse. For 
in  vivo studies, different doses of streptozotocin (STZ) 
are administered to mimic type 1 or type 2 DM. Exam-
ples of the CMs that have been investigated are Glycyr-
rhizauralensis (gan-cao), Carumcarvi (zang-hui-xiang), 
Allium sativum (da-suan), and Mesonaprocumbens 
(xian-cao) [11–14]. In addition, alloxan (ALX)-induced 
mice, db/db mice, KK-Ay mice, and Otsuka Long-Evans 
Tokushima Fatty (OLETF) rats have been reported for 
investigation of CMs in DN treatment [15–18]. Mean-
while, glomerular endothelial cells, mouse podocyte 
cells, renal proximal epithelial cells, murine hepatocytes, 
mouse mesangial cells, and human mesangial cells are 
used as in  vitro models for anti-DN mechanism stud-
ies [19–27]. By applying these models, the majority of 
studies have reported that CMs such as Acacia nilotica 
pods (jin-he-huan) [28], Artemisia campestris (huang-
ye-hao) [29], Paeonialactiflora (shao-yao) [30], and 
Open Access
Chinese Medicine
*Correspondence:  scwtang@hku.hk; ybzhang@hku.hk 
1 School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The 
University of Hong Kong, 10 Sassoon Road, Hong Kong, People’s Republic 
of China
2 Department of Medicine, Li Ka Shing Faculty of Medicine, The University 
of Hong Kong, 10 Sassoon Road, Hong Kong, People’s Republic of China
Full list of author information is available at the end of the article
Page 2 of 12Liu et al. Chin Med  (2016) 11:6 
Schisandra chinensis (wu-wei-zi) [21, 31] exhibited ben-
eficial effects on all stages of experimental DN and may 
protect multiple organs. Grapevine leaf (Vitis labrusca) 
extract was reported to exert hepatoprotective, cardio-
protective, and renoprotective effects [32]. Moreover, 
CM preparations such as Fufang Xueshuantong Capsule 
(fu-fang-xue-shuan-tong-jiao-nang), Zhengqing Recipe 
(zheng-qing-fang), and Danggui Buxue Tang demon-
strated benefits for DN patients [33–35]. Representative 
CMs for the treatment of DN at different stages of dis-
ease progression and their underlying mechanisms are 
shown in Fig. 1.
This article aims to review the experimental evidence 
for the effectiveness of CMs in DN management, with 
emphasis on their underlying mechanisms, and to dis-
cuss the combined use of CM herbs and chemical drugs 
in DN treatment.
Search strategy and selection criteria
We searched for the terms “traditional Chinese medicine”, 
“holistic therapy”, and “traditional Chinese medicine pre-
scriptions (or formula)” in combination with “diabetic 
nephropathy” and “diabetes” in PubMed, Google Scholar, 
and Web of Science between 1990 and 2014. Manual 
searches of in-text references from the selected articles 
were further performed. Studies were included if in vivo 
models were used to investigate the nephroprotective 
effects and mechanisms of CMs. Unpublished reports, 
Letters to the Editor, and the studies that only used 
in vitro models or did not provide information about the 
duration of animal studies were excluded.
CMs in experimental DN management
CMs intervention in the early stage of experimental DN
The potential signaling pathways involved in DN patho-
genesis regulated by CMs are shown in Fig. 2. The early 
stage of DN is characterized by hyperfunction and 
hypertrophy arising from oxidative stress and inflamma-
tion [3, 36, 37]. Under chronic hyperglycemia, the extra-
cellular glucose forms advanced glycation end-products 
(AGEs). Activation of receptor of advanced glycation 
end-products (RAGE) on the plasma membrane has 
been proposed to contribute predominantly to the over-
production of reactive oxidative species (ROS) [38]. 
a b
c
Fig. 1 Natural course of diabetic nephropathy (DN) progression and Chinese medicine (CM) interventions in different stages. a In the early stage 
characterized by hyperfiltration and hypertrophy, CMs have therapeutic effects based on their anti‑oxidant or anti‑inflammatory activities. Repre‑
sentatives are Panax quinquefolium, Asparagus racemosus, Rosa laevigata, and Piper auritum [5, 42–44]. b In the incipient DN stage characterized by 
microalbuminuria, CMs such as Cornus officinalis, Abelmoschus manihot, Schisandrae chinensis, and Paeonia lactiflora exhibit anti‑microalbuminuric 
effects and may slow down the propagation of DN [19, 21, 46, 47]. The mechanisms involve protecting podocytes, and suppressing extracellular 
matrix (ECM) expansion and the endothelin‑reactive oxidative species (ET‑ROS) axis. As both the early and incipient stages of DN are at least partially 
reversible, CM interventions, which have superior effects based on their anti‑oxidant, anti‑inflammatory, and other renoprotective activities, are rec‑
ommended as early as possible. c In the overt and end‑stage renal disease (ESRD) stages of DN characterized by proteinuria and glomerulosclerosis, 
respectively, CM prescriptions, such as Zhen‑wu‑tang (ZWT; also called Shinbu‑to in Japan) consisting of five herbs including Common Monkshood 
root, Poria, White Peony root, Atractylodis rhizome, and Zingiberis rhizome, have demonstrated optimal effects on ameliorating proteinuria by sup‑
pressing the hyperactivity of the renal renin–angiotensin system [72]
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Meanwhile, the polyol pathway of glucose metabolism 
activated by the intracellular glucose further aggravates 
the oxidative stress. Other major sources of excess ROS 
were reported to be enhanced protein kinase C (PKC) 
activity caused by activation of the polyol pathway [39] 
and mitochondrial ROS production in response to 
mitochondrial damage. As a consequence, nuclear fac-
tor (NF)-κB becomes activated, followed by stimulation 
of pro-inflammatory cytokines (e.g., interleukin [IL]-
6), chemokines (e.g., monocyte chemoattractant pro-
tein [MCP]-1), adhesion molecules (e.g., intercellular 
adhesion molecule 1 [ICAM1], vascular cell adhesion 
protein 1 [VCAM1]), and nuclear receptors (e.g., per-
oxisome proliferator-activated receptor [PPARs]) [40]. 
Thereafter, the inflammation induces endoplasmic retic-
ulum (ER) stress via unfolded protein response path-
ways, resulting in metabolic disorders and apoptosis. 
Besides, subsequent macrophage infiltration into renal 
tissues leads to prolonged micro inflammation, thus 
aggravating the progression of DN. Numerous CMs are 
applied at this point to control this reversible stage of 
DN [41]. Asparagus racemosus (lu-sun), Radix Astragali 
(huang-qi), Rosa laevigata (jin-ying-zi), and Piper auri-
tum (hu-jiao) were reported to enhance the activities of 
superoxide dismutase (SOD) and glutathione peroxi-
dase (GSH-Px), leading to attenuation of the oxidative 
stress [5, 42–44].
CMs intervention in the incipient stage of experimental DN
The development of micro albuminuria was reported as 
an indicator of the incipient stage of DN, arising from 
endothelial dysfunction [38, 45]. Renal hypertrophy and 
hyperfiltration induced functional and structural altera-
tions, resulting in micro albuminuria and hypertension, 
leading to glomerulus sclerosis, and progressing to incip-
ient DN. Cornus officinalis (shan-zhu-yu), Abelmoschus 
manihot (huang-shu-kui), Schisandrae chinensis (wu-wei-
zi), and Paeonia lactiflora (shao-yao) were reported to 
exhibit anti-micro albuminuria effects, thereby slowing 
down DN progression [19, 21, 46, 47].
Fig. 2 Potential signaling pathways involved in diabetic nephropathy (DN) pathogenesis. Activation of receptor of advanced glycation end‑
products (RAGE) by advanced glycation end‑products (AGEs) results in reactive oxidative species (ROS) overproduction, leading to oxidative stress. 
Meanwhile, the polyol pathway activated by intracellular glucose further aggravates the oxidative stress. Activation of protein kinase C (PKC) via the 
polyol pathway is another major source of ROS production. Mitochondrial damage also contributes to ROS production. ROS overproduction and 
impaired anti‑oxidant response cause oxidative stress, which activates nuclear factor (NF)‑κB and upregulates monocyte chemoattractant protein 
(MCP)‑1, interleukin (IL)‑6, tumor necrosis factor (TNF)‑α, and transforming growth factor (TGF)‑β. Thereafter, the inflammation induces endoplasmic 
reticulum (ER) stress via unfolded protein response pathways, resulting in metabolic disorders and apoptosis
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CMs intervention in the overt and end‑stage renal disease 
(ESRD) stages of experimental DN
After the incipient stage of DN and under hyperglyce-
mic conditions, mesangial nodules and tubule intersti-
tial fibrosis develop, leading to proteinuria and nephrotic 
syndrome, and eventually to the overt stage of DN, which 
is characterized by persistent proteinuria [6]. Without 
effective control, patients in this stage will deteriorate 
to ESRD with uremia. As the kidney disease progresses, 
physical changes in the kidneys often lead to increased 
blood pressure and cardiovascular disease. In this stage, 
angiotensin-converting enzyme (ACE) inhibition is the 
conventional intervention [48]. The goal of treatment 
is to prevent the progression from micro albuminuria 
to macro albuminuria, and multiple and more intensive 
strategies are strongly advised. Avosentan was reported 
to reduce albuminuria in patients with type 2 DM and 
overt nephropathy by inhibiting ACE and blocking angi-
otensin receptors, but can also induce significant fluid 
overload and congestive heart failure [49]. Averrhoa 
carambola L. (yang-tao), Salvia miltiorrhiza (dan-shen), 
and Picrorrhiza Rhizoma (hu-huang-lian) can ameliorate 
DN symptoms safely [50–52]. Representative CMs and 
their related mechanisms are summarized in Table 1.
Besides targeting the specific molecules involved in DN 
pathogenesis to exert anti-hyperglycemic and nephro-
protective effects, CM has unique characteristics in DN 
management. In CM, DN is not only a kidney disease, 
but also an embodiment of the systemic disease in the 
kidney, which is in accordance with the latest findings 
for DN pathogenesis [7, 8, 38]. The pathogenesis of DN 
may be closely related to the dysfunction or impairment 
of other organs, and therefore treatments for diseases in 
other organs may be helpful for the amelioration of DN, 
especially in the overt and ESRD stages. The normal 
functioning of the human body relies on the coordina-
tion of yinand yang, and the five zang organs (wuzang), 
i.e., the liver (gan), heart (xin), spleen (pi), lung (fei), and 
kidney (shen), are respectively related to wood (mu), fire 
(huo), earth (tu), metal (jin), and water (shui) and con-
nected under the laws of inter promotion and interaction 
(Fig. 3) [53]. Once a significant imbalance occurs, certain 
symptoms of the kidneys inevitably and predictably arise.
Under hyperglycemic conditions, the oxidative stress 
and inflammation affect the blood circulatory system, 
consequently leading to the dysfunction of multiple 
organs. Cardiovascular disease causes even more deaths 
than ESRD in patients with DN [38]. The degree of pul-
monary function impairment was found to be positively 
associated with the stage of DN progression [7]. Besides, 
liver X receptor (LXR) agonists, which are commonly 
used to treat hyperlipidemia and non-alcoholic fatty 
liver disease, were shown to ameliorate DN by inhibiting 
the expressions of osteopontin and other inflammatory 
mediators in the kidney cortex [8]. Moreover, during 
DN pathogenesis, glomerular hypertrophy was found to 
be associated with hyperinsulinemia [54], and has been 
proposed as a novel therapeutic target for DN [55]. As 
a systematic micro vascular thrombosis combined with 
metabolic disorders, DN influences the whole internal 
environment, and its pathogenesis may be closely related 
to the dysfunction of other organs.
From this perspective, CM as a therapeutic approach 
targeting multiple organs is preferred to improve the 
overall health of DN patients. Experimentally, grapevine 
(Vitis labrusca L.) leaves exhibited hepatoprotective, car-
dioprotective, and renoprotective effects in Wistar rats 
[32]. Besides, extracts from S. miltiorrhiza exhibited a 
regulatory effect on the expression of LXR-α in hyperlipi-
demic rats [56]. Furthermore, Liuwei Dihuang Decoction 
exhibited a protective effect on early DN in STZ rats [57]. 
Additionally, a CM prescription, kangen-karyu, exhibited 
hepatoprotective/renoprotective activities through the 
inhibition of AGE formation and fibrosis-related pro-
tein expressions in type 2 diabetes [58]. Yamabe and col-
leagues systematically conducted a series of experiments 
to investigate the anti-diabetic effects of a CM prescrip-
tion, hachimi-jio-ga, and reported findings for the whole 
prescription and its constituents as well as for the bio-
active compound [59–64]. Other selected CM prescrip-
tions for DN treatments and their respective molecular 
mechanisms are shown in Table  2. In particular, single 
herbs (e.g., Auricularia auricula, hei-mu-er) and CM 
prescriptions (e.g., Danggui Buxue Tang and Gui Qi Mix-
ture) produced better beneficial effects than conventional 
anti-DN drugs by regulating blood lipid metabolism 
and lipoprotein lipase activity through the regulation of 
blood glucose based on their complex compound matri-
ces [65–67]. The changes in blood glucose, triglyceride 
(TG), total cholesterol (TC), and high-density lipoprotein 
(HDL) were reversed by Gui Qi Mixture, but not by the 
ACE inhibitor benazepril in diabetic rats [68]. Similarly, 
the increases in fasting blood glucose (FBG), TG, and TC 
were attenuated, and the renal kidney/body weight (K/B) 
ratio, urinary albumin excretion (UAE), and creatinine 
clearance rate (CCr) in STZ-induced diabetic rats were 
ameliorated after 8  weeks of treatment with Danggui 
Buxue Tang compared with benazepril [69]. Collectively, 
CMs may exert synergetic effects targeting multiple 
organs, and benefiting the whole internal milieu of DN 
patients.
At the ESRD stage, it is almost impossible to prevent 
the disease from becoming more severe, and dialysis may 
be the final resort for these patients. To provide a more 
cost-effective therapeutic approach, other potent rem-
edies are urgently needed. In this regard, the combined 
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use of herbs and drugs, and the development of new 
therapies are receiving increasing attention.
Modern drugs specifically aim to target disease-related 
molecules through definite pathways, whereas CM aims 
to exert synergetic effects and benefit the whole inter-
nal milieu of patients, leading to the possibility that the 
combined use of CMs and modern drugs may exert bet-
ter therapeutic effects on diseases, especially for chronic 
and comprehensive DN. Currently, the combined use of 
herbs and drugs in the treatment of DN has been well-
investigated. For example, the CM prescription tangshen-
ling was combined with telmisartan to treat 80 patients 
with DN, and exhibited a better effect than telmisartan 
treatment alone [70]. Basic research corroborated that 
the tangshenling mixture had a synergetic effect with 
benazepril through a different signaling pathway, which 
involved down regulation of atrial natriuretic factor 
(ANF) in plasma and glucose transporter 1 (GLUT1) in 
the kidney when treating DN [71]. Herbs may reduce the 
permeability of the drug into the intestinal tract, and may 
also affect its metabolism in the liver and cause hypo-
glycemia. Huang Kui capsule reduced the absorption 
of glibenclamide and accelerated its metabolism. This 
herb–drug interaction deserves further research on the 
herb–drug pharmacokinetic interaction to enhance the 
therapeutic effects and avoid side effects.
Limitations of this review
In many studies included in this review, the bioactivities 
of the CMs responsible for the anti-DN effects and their 
molecular targets were not identified. Phytochemical 
and molecular biological studies are needed to identify 
the bioactive constituents and to elucidate the underly-
ing mechanisms. Moreover, this review only focused on 
Fig. 3 Schematic diagram integrating the Chinese medicine (CM) view on the holistic therapy and modern pathogenesis concepts of diabetic 
nephropathy (DN). The core shows the holistic view of DN under CM theory, which is based on the Yin‑Yang and Five Elements theories. The regular 
functioning of the human body relies on the coordination of Yin and Yang in a unity of opposites, and the liver, heart, spleen, lung, and kidneys 
are respectively related to wood, fire, earth, metal, and water [53]. In particular, the spleen in CM is a functional organ that governs transport and 
transformation in a close relationship with the stomach and pancreas [73–75]. This theory reflects the unification and integration together with the 
impact caused by the breakdown of the balance as a consequence of overacting and counteracting relationships, which is of practical significance 
in CM clinical practice. The peripheral annotations imply recent therapeutic strategies against DN specific to individual organs. The solid arrows 
denote interpromoting relationships. The dashed arrows indicate interacting/counteracting relationships
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studies using in vitro or in vivo DN models. Results from 
clinical trials investigating the use of CMs for the treat-
ment of DN are needed to confirm the therapeutic effects 
of CMs in the future.
Conclusion
CMs provides an alternative for DN management in all 
stages of experimental DN models, especially in the early 
and incipient stages of DN, and the synergistic adminis-
tration of CM herbs with conventional drugs exhibited 
better efficacy than drugs alone in DN treatment.
Abbreviations
ANF: atrial natriuretic factor; AGEs: advanced glycation end products; Ang II: 
angiotensin II; ALX: alloxan; AR: aldose reductase; ACE: angiotensin‑converting 
enzyme; ARB: angiotensin receptor blocker; ACR: urinary microalbumin 
to creatinine ratio; BUN: blood urea nitrogen; BMP: bone morphogenetic 
protein; CAT: catalase; CCr: creatinine clearance rate; CGRP: calcitonin gene‑
related peptide; CHO: cholesterol; CTGF: connective tissue growth factor; 
CML: n(epsilon)‑(carboxymethyl)lysine; DM: diabetes mellitus; DN: diabetic 
nephropathy; ER: endoplasmic reticulum; ET‑1: endothelin‑1; ESRD: end‑stage 
renal disease; EMT: epithelial‑to‑mesenchymal transition; ECM: extracel‑
lular matrix; EMMPRIN: extracellular matrix metalloproteinase inducer; ERK: 
extracellular signal‑regulated kinases; ED‑1: monocyte/macrophage; FBG: 
fasting blood glucose; FN: fibronectin; GA: glomerular area; GFR: glomerular 
filtration rate; GMCs: glomerular mesangial cells; GBM: glomerular basement 
membrane; GSH‑Px: glutathione peroxidase; GST: glutathione‑S‑transferase; 
GLUT: glucose transporter; HDL: high density lipoprotein; HFD: high fat diet; 
Hyp: hydroxyproline; iNOS: inducible nitric oxide synthase; ICAM: intercellular 
adhesion molecule; IGF: insulin‑like growth factor; K/B: kidney/body weight; 
LPO: lipid peroxidation; LPL: lipoprotein lipase; LXR: liver X receptor; LDL: low 
density lipoprotein; NAG: n‑acetyl‑beta‑D‑glucosaminidase; eNOS: endothe‑
lial nitric oxide synthase; nNOS: constitutive nitric oxide synthase; tNOS: 
total nitric oxide synthase; MAPK: mitogen‑Activated Protein Kinase; mALB: 
Table 2 Experimental studies on selected CM prescriptions in diabetes nephropathy management
AGEs advanced glycation end products, ANF atrial natriuretic factor, Ang II angiotensin II, BMP bone morphogenetic protein, BUN blood urea nitrogen, CCr creatinine 
clearance rate, CHO cholesterol, CML N(epsilon)-(carboxymethyl)lysine, CGRP calcitonin gene-related peptide, CTGF connective tissue growth factor, ET endothelin, 
FBG fasting blood glucose, GA glomerular area, GLUT glucose transporter, TGF transforming growth factor, FN fibronectin, GSH-Px glutathione peroxidase, HDL high 
density lipoprotein, HFD high fat diet, K/B kidney/body weight, NF-κB nuclear factor κB, NO nitric oxide, cNOS constitutive nitric oxide synthase, eNOS endothelial 
nitric oxide synthase, iNOS inducible nitric oxide synthase, nNOS constitutive nitric oxide synthase, tNOS total nitric oxide synthase, MDA malondialdehyde, MMP 
matrix metalloproteinase, β (2)-MG Urine β (2)-microglobin, OLETF otsuka long-Evans Tokushima Fatty, PGF prostaglandin F, SCr serum creatinine clearance rate, STZ 
streptozotocin, SOD superoxide dismutase, TGF transforming growth factor, TG triglyceride, TC total cholesterol, TARS thiobarbituric acid reactive substances, TXB(2) 
thromboxane B 2, UAE urinary albumin excretion rate, UAlb urinary microalbumin
CM preparations DN model Nephro-protective  
mechanisms
Pharmacodynamic  
indicators
Dosage Duration Ref.
Xiao‑chai‑hu‑tang STZ rat ↓TGF‑β1, FN, and collagen 
IV,↑BMP‑7, SOD
FBG, BUN, SCr, renal hyper‑
trophy
200 mg/kg b.w 4 weeks [100]
LiuweiDihuang Decoction STZ rat ↓MDA, iNOS, tNOS, cNOS, 
ET‑1, ET(A), ↑NO, MMP‑2, 
MMP‑9, GSH‑Px, SOD
FBG, plasma insulin level 5, 10, or 15 g/kg b.w 4 weeks [57]
Tangshenling mixture plus 
benazepril
STZ rat ↓ANF, GLUT1 UAE, CCr, K/B ratio 5 g/kg b.w 6 weeks [71]
DangguiBuxue Tang STZ rat ↓TGF‑β1 K/B ratio, UAE, β(2)‑MG 
concentrations, CCr, FBG, 
TC, TG
– 8 weeks [69]
Dang‑gui and Huang‑qi 
mixture
STZ rat ↓TGF‑β1, Ang II FBG, TG, CHO, HDL, SCr, CCr, 
BUN, β(2)‑MG,K/B ratio, GA
– 8 weeks [68]
Tangshenning Recipe STZ rat ↓TXB(2), TXB(2)/6‑keto‑PGF1 
α, CGRP, MDA; ↑ET, SOD, 
GSH
– 35 g/kg b.w 8 weeks [101]
Shenbao Recipe STZ rat ↓CTGF, ↑MMP‑9 UAlb, FBG, TC, SCr 13 g/kg b.w 8 weeks [102]
Wu‑ling‑san STZ rat ↓NF‑κB, TGF‑β1, FN, AGEs, 
mitochondrial TBARS, CML
UAE, UAlb, CCr, mesangial 
matrix expansion
2.5 g/kg b.w 10 weeks [103]
Zhen‑wu‑tang STZ rat ↓Ang II, ↑nephrin, podocin Body weight, polyurea, UAE, 
SCr, BUN
320 mg/kg b.w. 12 weeks [72]
FufangXueshuantong 
Capsule
HFD + STZ 
rat
↑GSH‑px, SOD UAE, CCr, masengial matrix 
expansion
450, 900, or 1800 mg/
kg b.w
12 weeks [104]
Hachimi‑jio‑gan STZ rat ↓AGEs, sorbitol FBG, UAE, CCr, serum 
glycosylated protein, BUN, 
serum albumin level, TG, TC
50,100, or 200 mg/kg b.w 15 weeks [59]
Kangen‑karyu STZ mouse ↓AGEs, TGF‑β1, collagen IV FBG, BUN 100, 200 mg/kg b.w 18 weeks [58]
Hachimi‑jio‑gan OLETF rats ↓NF‑κB, TGF‑β1, FN, iNOS, 
cyclooxygenase‑2, AGEs, 
TBARS
UAE, CCr, FBG 50, 100, or 200 mg/kg b.w 32 weeks [61]
Yiqiyangyinhuayutongluo 
recipe
HFD + STZ 
rat
↑Nephrin FBG, UAE, 24 h U‑nephrin 0.8 g/kg b.w 32 weeks [105]
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microalbuminuria; MDA: malondialdehyde; MMP: matrix metalloproteinase; 
MCP: monocyte chemotactic protein; OLETF: otsuka Long‑Evans Tokushima 
Fatty; PPAR: peroxisome proliferator‑activated receptor; PAI: plasminogen 
activator inhibitor; PK1: protein kinase 1; PGF: prostaglandin F; ROS: reactive 
oxidative species; RAGE: receptor of advanced glycation end‑products; SGK: 
serum and glucocorticoid induced protein kinase; STZ: streptozotocin; SOD: 
superoxide dismutase; α‑SMA: α‑smooth muscle actin; SCr: serum creatinine 
clearance rate; TGF: transforming growth factor; CM: chinese medicine; TARS: 
thiobarbituric acid reactive substances; TIMP: tissue inhibitor of metallopro‑
teinase; TG: triglyceride; TC: total cholesterol; TSP‑1: thrombospondin‑1; TXB(2): 
thromboxane B 2; UCr: urinary creatinine; β (2)‑MG: urine β (2)‑microglobin; 
UCP: uncoupling protein; UAlb: urinary microalbumin; UPR: unfolded protein 
response; UAE: urinary albumin excretion; VEGF: vascular endothelial growth 
factor.
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